Impact of COVID 19 on the Nervous System

Original Editor - Srishti Banerjee

Top Contributors - Srishti Banerjee, Kim Jackson and Aminat Abolade

One Page Owner - Srishti Banerjee as part of the One Page Project

Introduction[edit | edit source]

With the outbreak of coronavirus, the major areas of concern were the respiratory system. However, it has been established that coronavirus affection can extend beyond the respiratory system and one of the deadly areas of affection is the effect of the virus on the nervous system. A wide range of neurological manifestations have been reported during and post covid conditions.

Pathophysiology[edit | edit source]

Invasion via the olfactory route.[edit | edit source]

Loss of smell has been reported as one of the earliest symptoms of covid infection. It has been established by the evidence of an increase in MRI signal to the olfactory cortex suggestive of infection in the nervous system. The virus gains access to the central nervous system via the bloodstream, infecting the endothelial cells. Secondly the virus can enter the peripheral nervous system through retrograde neuronal routes[1]. The virus could be internalized in nerve terminals by endocytosis, transported retrogradely, and spread trans-synaptically to other brain regions[2]

Angiotensin-converting enzyme -2 ( ACE-2) receptor present in the nasal mucosa is exploited by the virus. ACE-2 receptor is also present in organs such as kidneys, lungs, and in tissues of the nervous system. The presence of ACE-2 receptors in the tissues of the nervous system is hypothesized to be the reason that the virus leads to neurological manifestations.

The virus from the general circulation can pass into the cerebral circulation, where due to sluggish movement of the blood in the microcirculation along with the high rate of the load from the initial sites of infection facilitates the interaction of a protein present in the coronavirus known as spike protein ( S protein ) with the ACE-2 receptors present in the capillary endothelium. Following this, there is the budding of the virus in the capillary endothelium leading to the spread of the virus in areas of the brain and brainstem via Virchow-Robin spaces surrounding arterioles and venules[3].

Cytokine Storm is another mechanism reported to be responsible for neurological manifestations in covid infection. Cytokine storm is defined as dysfunctional, uncontrolled, continuous activation of inflammation. This leads to acute respiratory distress syndrome, renal failure, myocardial injury, the severity of illness, the requirement of intensive care unit admission, the requirement of mechanical ventilation, and mortality. The presence of inflammatory markers such as C-reactive protein and leukocytes confirm the presence of cytokine storm. Diffuse illness of CNS has been reported and temporal association between inflammatory markers and CNS dysfunction is yet to be established[4]. However, it is known that the release of interleukin-6 causes vascular leakage and activation of complement and coagulation cascades, in addition to this patients with severe covid infection present with higher levels of D-dimer, which is a marker of a hypercoagulable state and endogenous fibrinolysis . These may be the factors that cause acute cerebrovascular disease. Cytokine storm is also responsible for causing arthralgia[1].

Pneumonia is a common clinical feature of covid infection, however, the systemic hypoxia occurring due to pneumonia causes damage to the brain cells and other nerve cells[1].

Peripheral vasodilatation, hypercarbia, hypoxia, and anaerobic metabolism, which ultimately result in neuronal swelling and brain edema, which leads to raised intracranial pressure resulting in headache, impaired consciousness, seizure, and irritation of the trigeminal nerve[1].

Immune dysregulation by the hypothalamus[1]: Several cytokines such as IL-6, IL-1β, and TNF are secreted during the covid infection and are powerful activators of the hypothalamic-pituitary-adrenocortical (HPA) axis The HPA axis is central to the regulation of systemic immune activation and is activated by blood-brain barrier dysfunction and neurovascular inflammation. The Covid infection leads to immunosuppression and lymphopenia which leads to activation of the HPA, leading to the release of norepinephrine and glucocorticoids. These mediators act synergistically to induce splenic atrophy, T cell apoptosis, and Natural killer cell deficiency. Downregulation of these factors, in concert with calprotectin release from damaged lungs, may increase hematopoietic stem cell proliferation skewed towards emergency myelopoiesis ( production of the bone marrow) which results in lymphopenia and neutrophilia, two key hematological features of COVID[1].

Covid infection can cause multi-system failure leading to systemic water, electrolyte imbalance, hormonal dysfunction, accumulation of toxic metabolites which is hypothesized to cause neurological manifestations such as headaches, confusion, agitation etc.

Neurological manifestations[5],[6],[7][edit | edit source]

The neurological manifestations during and after the infection include:

  • Encephalopathy manifests as an alteration in mental status which includes, confusion, disorientation, agitation, and somnolence. Encephalopathy also presents as delirium and coma which is due to hypoxia, renal failure, hypotension, high dose of sedatives, prolonged immobility and isolation.
  • Encephalitis manifests as fever, altered mental state, seizures, white blood cells in cerebrospinal fluid, and focal brain abnormalities on neuroimaging.
  • Acute cerebrovascular disease and brain perfusion abnormalities are due to hypercoagulable states during and following the infection. Presence of patchy microthrombi and infarction is present.
  • Brain leptomeningeal enhancement [1]
  • Dysexecutive syndrome [2]
  • Ataxia
  • Meningitis
  • Myelitis

Neurological manifestations related to the stay in the intensive care units(ICU)[2].[edit | edit source]

Altered mental status has been reported in patients with critical illness and prolonged ICU stay. Critically ill patients with acute respiratory distress syndrome (ARDS) who are mechanically ventilated experience delirium due to hypoxemia and administration of a high dose of sedatives.

Post-infectious neurological complications[2][edit | edit source]

There are delayed effects as the infection leads to dysregulation in the systemic immune system response. After the acute phase of the infection subsides the dysregulated immune system response affects both the central and peripheral nervous system. Acute disseminated encephalomyelitis and acute necrotizing hemorrhagic encephalopathy are reported in the CNS after the infection. Peripherally, several cases of Guillain-Barre syndrome, neuropathy caused by an immune attack on peripheral nerves, have been reported in patients with recent COVID-19. The Miller-Fisher variant of Guillain-Barre syndrome, characterized by cranial nerve involvement, has also been reported.

Neuropsychiatric manifestations of coronavirus[8][edit | edit source]

Patients infected with Covid undergo either isolated hospital stay or are home quarantined, this isolation has been found to have a huge impact on the psychological state of mind. Patients staying in isolation rooms for a prolonged duration with limited social interaction, lack of stimulation, and loss of freedom, which may result in anger, fear, restlessness, and irritability. Staying in isolation rooms can negatively impact psychological wellbeing, in addition to depression, anxiety, fear, and loneliness, the acute stress experienced by patients can activate immune system responses via amplification of the corticotropin-releasing factor system that regulates impulsivity and releases pro-inflammatory cytokines such as IL-6 and TNF- α that evoke behavioral changes aimed to protect self from injury or harm. Patients also experienced post-traumatic stress disorder.

Impact of coronavirus on autonomic nervous system (ANS)[9][edit | edit source]

Covid infection lasting for more than 12 weeks is termed chronic, the current emerging studies suggest that chronic covid infection affects the autonomic nervous system. This impact on the ANS can be either virus-mediated or immune-mediated disruption. Patients with a long-term covid infection present with orthostatic intolerance syndrome which includes orthostatic hypotension, vasovagal syncope, and postural orthostatic tachycardia syndrome. The underlying pathophysiology is an abnormal autoimmune response to orthostasis. The patient presents with palpitations, chest pain, and breathlessness which are common symptoms seen in long-term covid infection due to the release of epinephrine and norepinephrine as a result of orthostatic intolerance. Also due to the hypovolemia from the primary infection and prolonged bed rest, the levels of catecholamine are very high resulting in paradoxical vasodilation, sympathetic withdrawal, activation of the vagus nerve which clinically presents as dizziness, hypotension, and ultimately syncope.

The relationship between covid impacting the ANS can be explained based on the cytokine response storm to the primary infection. This cytokine response storm results in the activation of the sympathetic system which leads to the release of pro-inflammatory cytokines , conversely the vagal simulation results in an ant- inflammatory response and all this together attack the ANS.

However, alternatively, several studies show in addition to the above-mentioned mechanisms, the virus itself is potent enough to give rise to immune-mediated neurological syndromes. It has been found that autoantibodies such as muscarinic receptors and α/β adrenoreceptors are responsible for autonomic disorders.

Impact of covid 19 in patients with pre-existing neurological pathology[10],[11],[12][edit | edit source]

It is interesting to note that covid 19 has a more severe impact on patients with pre-existing neurological manifestations such as stroke, Parkinson's, dementia, etc. The potential neurotropism of SARS-CoV-2, with a possible detrimental effect on pre-existing neurological diseases, should also be taken into account.

It is found that patients with preexisting neurological deficits from stroke have poor outcomes after getting infected by Covid. Such patients are at a greater risk of ICU admission, poor discharge rate and using mechanical ventilation. The exact pathophysiology is yet unknown for these poor outcomes, but it has been established that this poor outcome is due to concurrent conditions such as old age, hypertension, cardiovascular disorders like arrhythmias, diabetes, low immunity-related. Such patients are also at risk of developing cardio-embolic events secondary to viral and bacterial infection or new cerebrovascular events secondary to thrombotic microangiopathy hypercoagulability leading to the macro-and micro-thrombi formation in the vessels, hypoxic injury, disruption of the blood and blood-brain barrier.

Patients with Parkinson's also have poor outcomes. It is found the most common cause of symptom exacerbation in patients with Parkinson’s disease was the infection, followed by anxiety, medication errors, poor adherence to the treatment regime, In addition to this COVID infection itself and other factors such as a change in the environment due to hospitalization interferes with the intake of medications leading to worsening of symptoms.

Patients with Dementia show worsening in cognitive performance and delirium because the infection induces production of the central nervous system and systemic secretion of cytokines and prostaglandin.

In patients with spinal cord injury, there is a worsening of pneumonia due to difficulty in spontaneous breathing and clearing secretions.

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Abdullahi A, Candan SA, Abba MA, Bello AH, Alshehri MA, Afamefuna Victor E, Umar NA, Kundakci B. Neurological and musculoskeletal features of COVID-19: a systematic review and meta-analysis. Frontiers in neurology. 2020 Jun 26;11:687.
  2. 2.0 2.1 2.2 Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020 Aug 19.
  3. MadaniNeishaboori A, Moshrefiaraghi D, Ali KM, Toloui A, Yousefifard M, Hosseini M. Central Nervous System Complications in COVID-19 Patients; a Systematic Review and Meta-Analysis based on Current Evidence. Archives of Academic Emergency Medicine. 2020;8(1).
  4. Mishra AK, Lal A, Sahu KK, George AA, Sargent J. Letter to the editor regarding “Neurological impact of coronavirus disease (COVID-19): Practical considerations for the neuroscience community”. World Neurosurgery. 2020 Oct;142:533.
  5. Xiangliang Chen ,  Sarah Laurent,  Oezguer A. Onurn,  Nina N. Kleineberg,  Gereon R. Fink, et al.  A systematic review of neurological symptoms and complications of COVID‑19 Journal of Neurology ,9 July 2020
  6. ArianMadani Neishaboori , DonyaMoshrefiaraghi , KosarMohamed Ali , Amirmohammad Toloui , Mahmoud Yousefifard ,Mostafa Hosseini. Central Nervous System Complications in COVID-19 Patients; a Systematic Review and Meta-Analysis based on Current Evidence Archives of Academic EmergencyMedicine. 2020; 8(1): e62
  7. Iadecola et al., Effects of COVID-19 on the Nervous System, Cell (2020),
  8. Hao, F., Tam, W., Hu, X. et al. A quantitative and qualitative study on the neuropsychiatric sequelae of acutely ill COVID-19 inpatients in isolation facilities. Transl Psychiatry 10, 355 (2020).
  9. Dani, M., Dirksen, A., Taraborrelli, P., Torocastro, M., Panagopoulos, D., Sutton, R., & Lim, P. B. (2021). Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clinical Medicine21(1), e63.
  10. Patel, U., Malik, P., Shah, D. et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol (2020).
  11. Romagnolo, A., Balestrino, R., Imbalzano, G. et al. Neurological comorbidity and severity of COVID-19. J Neurol (2020).
  12. Takafumi Kubota, Naoto Kuroda, Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review,Clinical Neurology and Neurosurgery, Volume 200,2021,106349,ISSN 0303-8467,